Fundraising Fox

Neonc Technologies Holdings

NASDAQ: NTHI

Westlake Village, US · Founded 2023 · Delaware corporation

NeOnc is a biopharmaceutical company developing a patented platform technology to transport therapeutics across the blood-brain barrier, including intranasal delivery formulations such as NEO100 and NEO400. It targets brain and central nervous system diseases like glioblastoma and other brain cancers, serving patients and partnering with pharmaceutical companies.

BiotechHealthtechMedical Devices

Founders & leadership

PW
PATRICK WALTERSinExecutive
AH
AMIR HESHMATPOURinExecutive
KG
KEITHLY GARNETTinExecutive
TC
THOMAS C CHENNamed on SEC filing
AC
ALAN CHIANGNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$126.6M disclosed across 7 rounds · 2023–2026

▶$5MraisedJun 2026 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Yousha Neman-EbrahimExecutive Officer
  • Bader Al MonawerDirector
  • Jim DelshadDirector
  • Amir F. HeshmatpourExecutive Officer, Director
  • THOMAS C CHENExecutive Officer, Director
  • Victoria MedvecDirector
  • Steven L. GiannottaDirector
  • Keithly GarnettExecutive Officer
  • David ChoiExecutive Officer
  • Ming-Fu ChiangDirector
Offering amount
$5M
Amount sold
$5M
Sales commissions
$400K
Proceeds to insiders
$1.3M
Placement agents
Dawson James Securities, Inc.
First sale
Jun 2026
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.6MraisedFeb 2026 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven GiannottaDirector
  • Victoria MedvecDirector
  • Ming-Fu (Alan) ChiangDirector
  • AMIR HESHMATPOURExecutive Officer, Director
  • THOMAS C CHENDirector
  • Jim DelshadDirector
  • KEITHLY GARNETTExecutive Officer
  • Bader AlmonawerDirector
  • YOUSHA NEMAN-EBRAHIMExecutive Officer
Offering amount
$36M
Amount sold
$10.6M
First sale
Jan 2026
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedDec 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jim DelshadDirector
  • THOMAS C CHENDirector
  • Bader AlmonawerDirector
  • YOUSHA NEMAN-EBRAHIMExecutive Officer
  • KEITHLY GARNETTExecutive Officer
  • ISHWAR KANWAR PURIDirector
  • Steven GiannottaDirector
  • AMIR HESHMATPOURExecutive Officer, Director
  • Victoria MedvecDirector
  • Ming-Fu (Alan) ChiangDirector
Offering amount
$1M
Amount sold
$1M
First sale
Dec 2025
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.6MraisedApr 2025 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jim DelshadDirector
  • Steven GiannottaDirector
  • AMIR HESHMATPOURExecutive Officer, Director
  • Victoria MedvecDirector
  • Bader AlmonawerDirector
  • KEITHLY GARNETTExecutive Officer
  • PATRICK WALTERSExecutive Officer
  • Ming-Fu (Alan) ChiangDirector
  • THOMAS C CHENExecutive Officer, Director
Offering amount
$2M
Amount sold
$1.6M
First sale
Mar 2025
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedMar 2025 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • THOMAS C CHENExecutive Officer, Director
  • PATRICK WALTERSExecutive Officer
  • AMIR HESHMATPOURExecutive Officer, Director
  • KEITHLY GARNETTExecutive Officer, Director
Offering amount
$10M
Amount sold
$10M
Sales commissions
$300K
First sale
Mar 2025
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$18.3MraisedOct 2024 · 32 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • THOMAS C CHENExecutive Officer, Director
  • PATRICK WALTERSExecutive Officer
  • AMIR HESHMATPOURExecutive Officer, Director
  • KEITHLY GARNETTExecutive Officer, Director
Offering amount
$18.7M
Amount sold
$18.3M
First sale
Jul 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$80MraisedJul 2023 · 67 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • KEITHLY GARNETTExecutive Officer, Director
  • PATRICK WALTERSExecutive Officer
  • THOMAS C CHENExecutive Officer, Director
  • AMIR HESHMATPOURExecutive Officer, Director
  • ALAN CHIANGDirector
Offering amount
$80M
Amount sold
$80M
First sale
Apr 2023
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap
TradingView16 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Robinhood14 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits14 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Seeking Alpha13 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

Companies competing with Neonc Technologies Holdings for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Neonc Technologies Holdings do?
NeOnc is a biopharmaceutical company developing a patented platform technology to transport therapeutics across the blood-brain barrier, including intranasal delivery formulations such as NEO100 and NEO400. It targets brain and central nervous system diseases like glioblastoma and other brain cancers, serving patients and partnering with pharmaceutical companies.
How much funding has Neonc Technologies Holdings raised?
Neonc Technologies Holdings has disclosed $126.6M raised across 7 rounds.
Where is Neonc Technologies Holdings headquartered?
Neonc Technologies Holdings is headquartered in Westlake Village, US.